Tavros Therapeutics is a precision oncology platform company leading the new frontier of targeted therapies exploiting tumors’ genetic vulnerabilities. Tavros is also leveraging its proprietary platform and map of useful synthetic lethal relationships to build a highly innovative pipeline of category-defining small-molecule drug candidates. Based in Research Triangle Park, N.C., management is comprised of successful serial entrepreneurs with deep expertise in functional genomics, tumor genetics and drug discovery.